Sumitomo Mitsui Trust Group Inc. Acquires 1,070 Shares of Edwards Lifesciences Co. (NYSE:EW)

Sumitomo Mitsui Trust Group Inc. raised its holdings in Edwards Lifesciences Co. (NYSE:EW) by 0.1% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,365,272 shares of the medical research company’s stock after acquiring an additional 1,070 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned approximately 0.23% of Edwards Lifesciences worth $90,094,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Park Avenue Securities LLC grew its position in shares of Edwards Lifesciences by 0.5% during the 2nd quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company’s stock worth $2,169,000 after buying an additional 108 shares in the last quarter. City State Bank grew its position in shares of Edwards Lifesciences by 16.5% during the 2nd quarter. City State Bank now owns 917 shares of the medical research company’s stock worth $85,000 after buying an additional 130 shares in the last quarter. Stableford Capital II LLC grew its position in shares of Edwards Lifesciences by 2.7% during the 2nd quarter. Stableford Capital II LLC now owns 6,104 shares of the medical research company’s stock worth $533,000 after buying an additional 159 shares in the last quarter. Purus Wealth Management LLC grew its position in shares of Edwards Lifesciences by 5.2% during the 2nd quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company’s stock worth $297,000 after buying an additional 160 shares in the last quarter. Finally, Busey Bank grew its position in shares of Edwards Lifesciences by 1.9% during the 2nd quarter. Busey Bank now owns 8,838 shares of the medical research company’s stock worth $816,000 after buying an additional 165 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 1.1 %

Shares of NYSE:EW opened at $66.52 on Thursday. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The stock has a market cap of $39.23 billion, a price-to-earnings ratio of 9.60, a PEG ratio of 3.70 and a beta of 1.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average price of $67.47 and a 200-day moving average price of $76.51.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period last year, the business posted $0.59 earnings per share. Equities analysts predict that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,077,593.52. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,077,593.52. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 41,250 shares of company stock valued at $2,744,438 over the last ninety days. Company insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Baird R W cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 25th. Daiwa Capital Markets upgraded Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research note on Wednesday, July 31st. Morgan Stanley restated an “equal weight” rating and set a $70.00 price objective on shares of Edwards Lifesciences in a research note on Friday, October 11th. JPMorgan Chase & Co. upped their price objective on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Finally, Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Seventeen equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus price target of $75.67.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.